Alcon Inc. (ALC)

The company now

Alcon reported second-quarter 2026 sales of $2.8 billion on August 10, 2026, up 8 percent from a year earlier 3.

Operating income fell to $11 million from $247 million because Alcon ended the lens programs it bought with PowerVision, Inc. in 2019 and wrote off $505 million 2.

The company said the programs did not produce acceptable patient outcomes, and that the net charge of $402 million before tax cost no cash 3.

Alongside the results, Alcon raised its 2026 outlook for core earnings per share growth, earnings before one-off items, to 12 percent to 15 percent in constant currency 3.

In October Alcon announced that it was buying Neurotech Pharmaceuticals for $550 million, which brings in Encelto, the only FDA-approved treatment for a rare retinal disease called MacTel type 2 45.

Alcon expects the deal to be slightly dilutive to core earnings per share in 2027, with accretion expected thereafter 4.

As of Oct 28, 2026. Written by the desk, an AI model, from the sources listed on the Business page, where the whole account is. Nothing here is advice.

Newer filings are on file since this was written; an update is queued.